Home Healthcare IT Cell Line Development Market Companies, Report to 2031

Cell Line Development Market

Cell Line Development Market Size, Share & Trends Analysis Report By Product (Equipment, Reagents and Media, Accessories and consumables, Services), By Source (Mammalian, Non-Mammalian), By Type (Recombinant Cell Lines, Hybridomas, Continuous Cell Lines, Primary Cell Lines), By Applications (Bioproduction, Drug Discovery, Tissue Engineering, Others) and By Region(North America, Europe, APAC, Middle East and Africa, LATAM) Forecasts, 2023-2031

Report Code: SRHI3691DR
Study Period 2019-2031 CAGR 11.50%
Historical Period 2019-2021 Forecast Period 2023-2031
Base Year 2022 Base Year Market Size USD 5,691 Million
Forecast Year 2031 Forecast Year Market Size USD 15159 Million
Largest Market North America Fastest Growing Market Europe
The sample report only takes 30 secs to download, no need to wait longer.

Market Overview

The global cell line development market was valued at USD 5,691 million in 2022. It is estimated to reach USD 15,159 million by 2031, growing at a CAGR of 11.50% during the forecast period (2023–2031). Factors like increasing application of cell lines in biotech and pharmaceutical companies and hospitals drive market growth.

Cell line development is an essential part of research and biological drug manufacturing. Cell lines are developed through manipulating, discovering, and cloning single cells. Cell line creation is used in the lab to test cytotoxicity and drug metabolism and to study gene function to produce vaccines, antibodies, and cell therapies. Human cell lines are capable of producing proteins that are similar to those that are created naturally in the human body. This property benefits the development of protein therapies and propels the biopharmaceutical industry's expansion. The expansion of these sectors drives rising demand for cell line development. The likelihood that the resulting recombinant protein will include post-translational changes compatible with the native human proteins is one benefit of employing human cell lines for protein production.

Market Dynamics

Global Cell Line Development Market Drivers

Rising R&D in the Pharmaceutical and Biotechnology Industries

Increasing R&D in the pharmaceutical and biotechnology industries to cater to the rising need for treating various chronic diseases is increasing the use of cell line development equipment. In research projects, cells are used as a model system to study cell chemistry and cell biology for understanding the interaction between cells and infectious agents such as viruses and bacteria. The cells are also used in drug screening to study the effect of drugs on human cells. The market is growing as a result of increased spending on healthcare research.

The development of automated cell culture equipment has also been fueled by expanding R&D in the pharmaceutical and biotechnology sectors. This innovation is anticipated to be the driving force behind the cell line development industry. As a result, the pharmaceutical and biopharmaceutical sectors are expanding, contributing to the growth of the worldwide cell line development market in the coming years. This growth is propelled by increased R&D spending by pharmaceutical and biotech companies and various healthcare organizations.

Increasing Application of Cell Lines in Biotech and Pharmaceutical Companies and Hospitals

Continuous cell lines are used by numerous pharmaceutical and biotech-based companies as a specimen for testing drug efficacy. Due to this, there is a reduction in the use of gnotobiotic animals such as rabbits, mice, and monkeys. Moreover, as these cell lines have a long shelf life and can be preserved via cryopreservation and lyophilization techniques, several biotech and pharmaceutical companies prefer them over other media cultures for performing their R&D processes. The cell line culture technique bridges the gap between in-vitro and in-vivo culturing methods. It finds its application in cancer cell biology, drug discovery, and stem cell research, driving market growth.

Global Cell Line Development Market Restraint

High Maintenance Costs and Dearth of Skilled Staff

Stringent regulatory and licensing requirements coupled with the high initial investment for setting up a cell line culture laboratory hamper the growth of the cell line development market. Research laboratories and organizations need to make massive investments to maintain cell lines. This investment includes cold storage equipment, analytics equipment, laminar hoods, and more. Additionally, working with cell lines demands highly trained people, and a need for more qualified workers is estimated to restrain the expansion of the worldwide cell line development market during the assessment period. Thus, the high initial and maintenance costs of cell line development and maintenance are expected to hamper the growth of the global market as small-scale research laboratories and organizations find it unaffordable to procure and research.

Global Cell Line Development Market Opportunities

Rising Adoption of Mammalian Sources for Antibody Production

Organs or tissues obtained from mammalian or non-mammalian sources are used to start the cell line generation procedure. For the creation of stable cell lines suitable for commercial use, the source of this process is necessary. Therefore, the rising adoption of mammalian sources for producing antibodies and the increasing demand for expressing complex proteins similar to those described in humans are anticipated to provide significant growth opportunities. 

Additionally, mammalian cell lines are primarily used to produce recombinant urokinase as they provide posttranslational modifications. These cell lines have a broad spectrum of posttranslational modifications and authentic glycosylation and can carry out proper protein folding. Therapeutic antibodies are mainly produced in mammalian host cell lines involving PER, C6 human cells, NS0 murine myeloma cells, and Chinese Hamster Ovary (CHO) cells. Reduced infection risk and ease of adaptation to human tissues and biological components also contribute to increased adoption of mammalian cell lines. Hence, the abovementioned factors will likely present lucrative growth opportunities for the market players.

Regional Analysis

By region, the global cell line development market is divided into North America, Europe, Asia-Pacific, and the Rest of the World. 

North America Dominates the Global Market

North America is the most significant global cell line development market shareholder and is anticipated to grow at a CAGR of 11.71% during the forecast period. Research labs in North America are upgrading their procedures and using cell line development equipment for various reasons, including synthesizing therapeutic proteins, analyzing gene expression, producing vaccines, producing antibodies, and more. In addition, the market in the region is driven by the rising R&D expenditures in the pharmaceutical and biopharmaceutical industries, which are primarily focused on cell line creation. The combination of Brammer Bio's viral vector capabilities with Good Manufacturing Practice (GMP) production expertise, proprietary bioprocessing, and cell culture technologies uniquely positions it to partner with customers to drive the evolution of the cell line development market.

Europe is expected to grow at a CAGR of 10.57% over the forecast period. Key factors attributing to the market growth in the region are the launch of innovative technologies for cell line synthesis, an increase in various research activities for cell line development, and initiatives taken by the government to support the R&D activities. Europe is considered a significant hub in the biotechnology sector, owing to large biotechnology companies, high-tech research labs, and massive funding for R&D activities. Moreover, the key players in the region are involved in joint ventures and strategic partnerships. They are continuously investing in R&D to maintain their position in the market. 

Asia-Pacific is predicted to have the fastest-growing regional market throughout the assessment period due to the growing healthcare infrastructure, rising demand for monoclonal antibodies to treat conditions like cancer and myocardial disease, companies' use of cell lines for vaccine development, and government support for the region's biotechnology product regulations. The region's nations are well-developed, have clear laws and regulations, offer cheap labor, and have a sizable population of both short-term and chronically ill individuals. The growth in strategic initiatives such as product launches by established players, regional expansion, and strategic collaboration in the market are expected to be significant factors contributing to the growth of the cell line development market in the region. 

The expansion of the cell line development market in the Rest of the World is attributed to the technological advancements in cell line development and the high access to advanced healthcare technologies in research organizations in the UAE and Saudi Arabia. The Rest of the World cell line development market comprises the Middle East, Africa, and Latin America. The market in these regions is likely to grow due to rapidly improving healthcare infrastructure, increasing investments for cell line development by biopharmaceutical industries, and rising R&D in the biotechnology sector. 

Report Scope

Report Metric Details
By Product
  1. Equipment
  2. Reagents and Media
  3. Accessories and consumables
  4. Services
By Source
  1. Mammalian
  2. Non-Mammalian
By Type
  1. Recombinant Cell Lines
  2. Hybridomas
  3. Continuous Cell Lines
  4. Primary Cell Lines
By Applications
  1. Bioproduction
  2. Drug Discovery
  3. Tissue Engineering
  4. Others
Company Profiles Merck KGaA Thermo Fisher Scientific Inc. Lonza Fujifilm Holdings Corporation JSR Corporation Selexis SA Horizon Discovery Ltd. Rentschler Biopharma SE Boehringer Ingelheim International GmbH Sartorius Stedim Biotech
Geographies Covered
North America U.S. Canada
Europe U.K. Germany France Spain Italy Russia Nordic Benelux Rest of Europe
APAC China Korea Japan India Australia Taiwan South East Asia Rest of Asia-Pacific
Middle East and Africa UAE Turkey Saudi Arabia South Africa Egypt Nigeria Rest of MEA
LATAM Brazil Mexico Argentina Chile Colombia Rest of LATAM
Report Coverage Revenue Forecast, Competitive Landscape, Growth Factors, Environment & Regulatory Landscape and Trends
Need a Custom Report?

We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports

Segmental Analysis

The global cell line development market is segmented into product, source, type, and application.

By product, the global cell line development market is divided into equipment and reagents and media. 

The reagents and media segment is the highest contributor to the market and is expected to grow at a CAGR of 12.02% during the forecast period. There is a plethora of different equipment that is utilized during cell line development and its maintenance. The type of equipment used depends on the specific requirements of the cells that need to be cultured and proliferated. However, a few essential equipment types are used for cell line development processes, such as incubators, centrifuges, microscopes, cell counters, refrigerators and freezers, autoclaves, and cell culture hoods. All of them play crucial roles during cell line development and its maintenance. Additionally, innovations by key players in the market have driven growth for the equipment segment in the global cell line development market. 

Reagents and media play a crucial role in regulating the cell cycle and providing the desired growth rate to the researcher. Reagents include chemicals used to perform cell line development activities efficiently and with high reproducibility. Some common examples of reagents include buffers, cell adhesion reagents, substrates, and chelators. Media has four major components that help regulate the cells' growth cycle: basal media, glutamine, serum, and antibiotics. The surge in the production of vaccines and monoclonal antibodies is expected to increase demand for reagents and media. Additionally, key players are launching new products supplementing growth for the segment.

By source, the global cell line development market is divided into mammalian and non-mammalian cell lines. 

The mammalian segment owns the highest contributor to the market and is expected to grow at a CAGR of 12.04% over the forecast period. The mammalian cell line is developed by research into developmental biology and gene and protein interaction. Adopting mammalian cell lines will fuel market growth over the projection period due to their ease of adaptation to human tissues and biological components and the lower risk of infection. In addition, advances in cell line development technologies and rising usage of cell line development from mammalian sources for research, clinical, and pharmaceutical applications are also anticipated to drive the growth of the mammalian segment during the forecast period.

Non-mammalian cell culture is the culturing of cells derived from insects and amphibians. Using insect cell lines as production hosts is a new biopharmaceutical manufacturing technique. Furthermore, the rising prevalence of chronic diseases such as cardiovascular disorders, diabetes, asthma, and cancer demands effective and advanced treatment solutions, boosting the need for vaccines, biosimilars, novel drugs, and therapeutic proteins. Hence, the rise in chronic disorders drives the market growth. 

By type, the global cell line development market is divided into recombinant cell lines, hybridomas, continuous cell lines, and primary cell lines. 

The recombinant cell lines segment is the highest contributor to the market and is estimated to grow at a CAGR of 11.90% during the forecast period. Recombinant cell lines can be defined as cell lines into which recombinant DNA has been introduced. Such cell lines aid in the production of recombinant proteins. Recombinant cell lines are produced with the help of an expression vector that holds the recombinant DNA and its transfection into the host system, followed by a stringent selection and evaluation process to isolate only the transfected cells and their propagation. Factors such as the rising demand for recombinant proteins and the adoption of recombinant cell lines of biotherapeutics are driving demand for this segment. 

A continuous cell line is made up of a single type of cell that can be grown in culture repeatedly, either for a few cell divisions or forever. Cell lines with a fixed lifespan are usually diploid and differentiate to some extent. Continuous cell lines that can divide indefinitely have been transformed into tumor cells. Tumor cell lines are frequently obtained from real-life malignancies, but viral oncogenes or chemical therapies can also cause transformation. Transformed cell lines have the advantage of infinite availability, but they also have the disadvantage of retaining very few of the original in vivo features. Further, the increasing adoption of these cell lines in biopharmaceutical industries is driving the growth of the segment in the global market during the forecast period.

By application, the global cell line development market is divided into bioproduction, drug discovery, tissue engineering, and others. 

The bioproduction segment owns the highest contributor to the market and is anticipated to grow at a CAGR of 11.61% over the forecast period. Bioproduction is the manufacture of biologics-based therapeutic medications, such as protein-based medications, vaccines, gene therapies, and cell therapies, which are so complex that they can only be manufactured in living systems. The market growth of the bioproduction segment is mainly due to the increasing demand for biological products to treat various chronic and infectious diseases such as HIV, Hepatitis B, and tuberculosis. Moreover, the technological advancements resulting in the development of superior techniques for bioproduction are driving the market growth. The bioproduction segment is further segmented into antibody production, enzyme production, hormone production, and others.

Tissue engineering is a rapidly growing field that aims to repair, replace, or regenerate tissues or organs through cell line development equipment. The growth of the tissue engineering segment is mainly attributed to the increasing applications of cell line development equipment in tissue engineering and regenerative medicines. Cell lines are used in tissue engineering to develop new cures for degenerative and age-related diseases. Additionally, to overcome the drawbacks of organ transplantation, such as donor shortage and the need for immunosuppressive therapy, tissue engineering aims to trigger tissue-specific regeneration mechanisms by using cell line technology to contribute to the segment's growth. 

Market Size By Product

Recent Developments

  • January 2023- Berkeley Lights, Inc., a life sciences tools company, announced the launch of the Beacon Select™, the company's new optofluidic system for cell line development (CLD).
  • November 2022- Lonza introduced a ground-breaking new capsule solution for enteric (intestinal) drug delivery. The Capsugel® EnprotectTM capsule only releases its contents in the intestine and does not disintegrate during stomach transit. Capsugel® EnprotectTM capsules make it much easier to make drug products because they do not need to be coated or sealed in any other way.

Top Key Players

Merck KGaA Thermo Fisher Scientific Inc. Lonza Fujifilm Holdings Corporation JSR Corporation Selexis SA Horizon Discovery Ltd. Rentschler Biopharma SE Boehringer Ingelheim International GmbH Sartorius Stedim Biotech Others

Frequently Asked Questions (FAQs)

What is the estimated growth rate (CAGR) of the global cell line development market?
The global market growing at a CAGR of 11.50% from (2023–2031).
The growing application of cell lines in biotech and pharmaceutical firms and hospitals is the major growth factor of the market.
North America region has the largest share of the market.
Key verticals adopting cell line development include: - Merck KGaA, Thermo Fisher Scientific Inc., Lonza, Fujifilm Holdings Corporation, JSR Corporation, Selexis SA, Horizon Discovery Ltd., Rentschler Biopharma SE, Sartorius Stedim Biotech.
The reagent and media segment is expected to dominate over the forecast period.

We are featured on :

This website uses cookies to ensure you get the best experience on our website. Privacy Policy